Metabolic Category
THE APPETITE CONTROLLER
Ozempic; Wegovy; Rybelsus
Semaglutide is an FDA-approved GLP-1 receptor agonist that has transformed treatment of obesity and type 2 diabetes. It works by mimicking the hormone GLP-1 to reduce appetite, slow stomach emptying, and improve insulin sensitivity. In trials, it produced 15% weight loss and significantly reduced cardiovascular events. Available as weekly injection (Ozempic/Wegovy) or daily oral tablet (Rybelsus).
New to Semaglutide?
“I keep hearing about semaglutide for weight loss.”
01 · Translate it
Semaglutide is an active ingredient in prescription products with specific formulations and approved uses. A compound name alone does not identify the product or label.
02 · Check status
Find the exact brand, dosage form, manufacturer, and indication. Then use the current prescribing information for that product.
03 · Read in order
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Storage field guide
Check the brand, device, preparation state, and current label before using a day count.
This profile records Semaglutide as FDA approved.
Approval can be specific to a formulation, indication, and prescribing context, so review the regulatory and source details on this page.
Dose: Starting dose: 0.25 mg SubQ once weekly.
Schedule: weekly. Cycle: Ongoing as prescribed. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 1 curated or current research sources.
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Review the Semaglutide research sourcesReported side effects of Semaglutide include Nausea, Vomiting, Diarrhea, Constipation, and Injection site reactions.
They are reported or occasional reactions, not a prediction of what any one person will experience.
Semaglutide has an editorial safety grade of B (Good Safety).
FDA-approved with well-characterized side effects. GI issues are common but manageable. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
Activates hypothalamic POMC neurons to reduce hunger
Stimulates glucose-dependent insulin secretion
Delays stomach emptying for prolonged fullness
Reduces cardiovascular events and inflammation
Semaglutide was developed through Novo Nordisk's work on chemically modified GLP-1 peptides. Its design changes two positions in the GLP-1 sequence and attaches a fatty-diacid side chain through a linker at lysine 26. The discovery program examined both the peptide sequence and the albumin-binding side chain as separate parts of the molecule's design.
[Semaglutide discovery paper, Lau et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26308095/)
Those with type 2 diabetes · People with BMI over 30 (obesity) · Those with BMI over 27 with weight-related conditions · Anyone wanting proven, FDA-approved weight loss · Those at high cardiovascular risk
Build a week-by-week semaglutide titration schedule. Semaglutide is increased gradually roughly every four weeks to reach the maintenance dose.
Illustrative schedule based on the Wegovy label. This chart uses authored dose steps only; it does not allow custom dosing.
Reaches 2.4 mg in 20 weeks.
| Weeks | Dose | Note |
|---|---|---|
| 1–4 | 0.25 mg | starting dose |
| 5–8 | 0.5 mg | step |
| 9–12 | 1 mg | step |
| 13–16 | 1.7 mg | step |
| 17–20 | 2.4 mg | maintenance |
This chart is an educational example based on published labels or trial schedules. It is not medical advice and should not be used to start, stop, speed up or change a dose without medical supervision.
In-stock prices from 93 vendors, checked Oct 14, 2026.
Market evidence
We found certificates from a few of the Semaglutide vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
Certificate assessment
4 evaluated certificates
4 graded · 0 not graded · 1 in the A range.
Each result belongs to the named vendor’s certificate. Grades assess the document and its reported tests, not the vendor’s whole catalog or the safety of a product.
Automated checks can make mistakes. Open “Why this result?” for the reason and any review notice, and check the linked COA’s lot against your product. How grading works
4 evaluated records
Document grade
B3: Most of the evidence is there, but identity isn't confirmed, so the grade stops at A-.
Document check: flag.
Lab record: matched.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
26091202
Document grade
C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D.
Document check: flag.
Lab record: matched.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
1HBE
Document grade
X2: The certificate shows no identity test, so there is no evidence the vial contains the peptide on the label. Ask the vendor for a report that confirms identity by mass spectrometry.
Document check: fail.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
FF1011
Document grade
Review required
C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D.
Document check: flag.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
2024-01-24
| COA grade | Printed lab | Certificate | |||
|---|---|---|---|---|---|
| Prime Peptides Lot: 26091202 | Document grade Why this result?B3: Most of the evidence is there, but identity isn't confirmed, so the grade stops at A-. Document check: flag. Lab record: matched. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Freedom Diagnostics | Sep 18, 2026 | 99.7%99.5%+ | View COA |
| Oath Research Lot: 1HBE | Document grade Why this result?C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D. Document check: flag. Lab record: matched. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Freedom Diagnostics | Oct 21, 2025 | 99.865%99.5%+ | View COA |
| Atomik Labs Lot: FF1011 | Document grade Why this result?X2: The certificate shows no identity test, so there is no evidence the vial contains the peptide on the label. Ask the vendor for a report that confirms identity by mass spectrometry. Document check: fail. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Janoshik | Oct 21, 2024Older record | 99.643%99.5%+ | View COA |
| Skye Peptides Lot: 2024-01-24 | Document grade Review required Why this result?C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D. Document check: flag. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | MZ Biolabs | Feb 12, 2024Older record | 99.64%99.5%+ | View COA |
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. How to get a Semaglutide prescription
FDA-approved for weight loss. Patients lose 20%+ of their body weight.
from $0.95/mg · 277 vendorsNº 006 / 006Exercise in a molecule. Activate your metabolism without the gym
from $0.64/mg · 14 vendorsNº 002 / 006Get exercise benefits without the exercise
from $7.80/mg · 60 vendorsNº 005 / 006Boost metabolism and burn fat without changing your diet
from $0.90/mg · 124 vendorsNº 001 / 006Exercise in a peptide. Boost metabolism without the treadmill
from $1.20/mg · 178 vendorsNº 003 / 006Triple-action peptide with 24% average weight loss in trials.
from $1.70/mg · 347 vendorsNº 004 / 006
GLP-1 and metabolic peptides
Oral semaglutide reaches the blood at about 1% bioavailability through the absorption enhancer SNAC, so tablets need 3 to 14 mg. PIONEER trials show it works.
GLP-1 and metabolic peptides
Semaglutide cut weight 14.9% versus 2.4% on placebo in STEP 1 and reduced cardiovascular events in SUSTAIN-6 and SELECT. Substantial regain follows stopping.
